Seeking Alpha

Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System

HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the U ...
Business Insider

Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis SystemU.S. Regulatory Submission for DPP® HIV-Syphilis System Expected in Q1 2018

MEDFORD, N.Y., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced completion of the ...
Seeking Alpha

Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility

HAUPPAUGE, N.Y., May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (CEMI) (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced ...
Newsday

Chembio reports loss on sales of tests for HIV, syphilis in first quarter

Chembio Diagnostics Inc. lost money in the first three months of this year on lower sales of its tests for the infectious diseases HIV and syphilis. The Medford-based manufacturer reported Thursday a ...